| 13 OncoTherapy in Mesothelioma SG Gray, T Meirson, L Mutti Asbestos: Risk Assessment, Epidemiology, and Health Effects, 326, 2024 | | 2024 |
| 168 Receptor tyrosine kinase pathways and cell survival in mesothelioma P Bertino, N Aceto, D Barbone, S Busacca, L Mutti, G Gaudino Lung Cancer, S41, 2006 | | 2006 |
| 204 Proteasome inhibitors for treatment of malignant mesothelioma D Fennel, G Gaudino, C Porta, L Mutti Lung Cancer, S50, 2006 | 9 | 2006 |
| 24 Monitoring tumor growth by imaging of a human mesothelioma murine model P Bertino, S Pinato, L Mutti, F Piccardi, M Cilli, G Gaudino Lung Cancer, S6, 2006 | | 2006 |
| 64 Macrophage stimulating protein (MSP) up-regulates the Src kinases in malignant pleural mesothelioma AM Baird, D Easty, A Soltermann, D Nonaka, D Fennell, L Mutti, H Pass, ... Lung Cancer, S21, 2012 | | 2012 |
| 8: Are circRNAs potentially useful for the early detection of lung cancer? RC Lin, G Reid, L Mutti, AW Ryan, S Nicholson, N Leonard, V Young, ... Lung Cancer 1 (103), S4-S5, 2017 | | 2017 |
| 82 Inhibition of RON (MST1R) induces apoptosis and decreases the cellular migration and proliferation capacity of mesothelioma cells AM Baird, KJ O'Byrne, D Easty, A Soltermann, D Nonaka, DA Fennell, ... Lung Cancer, S29, 2013 | | 2013 |
| 87 Expression of SDHB in malignant pleural mesothelioma CJ Jennings, AG Manente, S Marciniak, G Pinton, D Rassl, L Mutti, ... Lung Cancer, S30, 2013 | | 2013 |
| 89 NF-kB provides a survival signal to human mesothelial and mesothelioma cells exposed to asbestos fibers D Barbone, C Porta, AS Bianchi, L Mutti, F Gasparri, G Gaudino Lung Cancer, S22, 2006 | 2 | 2006 |
| 96 Bortezomib accelerates BAX BAK dependent mitochondrial depolarization in malignant pleural mesothelioma cells A Chacko, G Coleman, P Harriott, B Greer, G Gaudino, L Mutti, D Fennell Lung Cancer, S23-S24, 2006 | | 2006 |
| A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people S Garritano, C De Santi, R Silvestri, O Melaiu, M Cipollini, E Barone, ... Journal of Thoracic Oncology 9 (11), 1662-1668, 2014 | 20 | 2014 |
| A drug screening revealed novel potential agents against malignant pleural mesothelioma I Dell’Anno, A Melani, SA Martin, M Barbarino, R Silvestri, M Cipollini, ... Cancers 14 (10), 2527, 2022 | 11 | 2022 |
| A glimpse in the future of malignant mesothelioma treatment G Pezzicoli, M Rizzo, M Perrone, S Minei, L Mutti, C Porta Frontiers in Pharmacology 12, 809337, 2021 | 3 | 2021 |
| A molecular epidemiology case control study on pleural malignant mesothelioma C Bolognesi, F Martini, M Tognon, R Filiberti, M Neri, E Perrone, E Landini, ... Cancer Epidemiology Biomarkers & Prevention 14 (7), 1741-1746, 2005 | 42 | 2005 |
| A Phase II study with the anti-CTLA-4 mAb tremelimumab in chemotherapy-resistant advanced malignant mesothelioma: safety, tolerability, clinical and immunologic activity L Calabro, AM Di Giacomo, A Morra, O Cutaia, E Fonsatti, R Danielli, ... JOURNAL OF THORACIC ONCOLOGY 6 (6), S535-S535, 2011 | 3 | 2011 |
| A pilot phase II clinical trial of the 20S proteasome inhibitor bortezomib in patients with relapsed malignant pleural mesothelioma DA Fennell, J Van Meerbeeck, KJ O'Byrne, P Donnellan, S O'Reilly, ... JOURNAL OF THORACIC ONCOLOGY 4 (9), S457-S458, 2009 | | 2009 |
| A polysome-based microRNA screen identifies miR-24-3p as a novel promigratory miRNA in mesothelioma S Oliveto, R Alfieri, A Miluzio, A Scagliola, RS Secli, P Gasparini, ... Cancer research 78 (20), 5741-5753, 2018 | 31 | 2018 |
| A PRECLINICAL INVESTIGATIVE PLATFORM SETUP, AS A TOOL FOR EVALUATING THE EFFICACY OF CETUXIMAB IN ADDITION TO THE STANDARD HUMAN MALIGNANT MESOTHELIOMA CHEMOTHERAPY PROTOCOL. M Ardizzone Università degli Studi di Milano, 2013 | | 2013 |
| Abemaciclib for malignant pleural mesothelioma V Nardone, C Porta, R Giannicola, P Correale, L Mutti The Lancet Oncology 23 (6), e237, 2022 | 4 | 2022 |
| Abemaciclib for malignant pleural mesothelioma–Authors' reply DA Fennell, N Nusrat The Lancet Oncology 23 (6), e238, 2022 | 2 | 2022 |
